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Cardiac magnetic resonance imaging (CMR) has long
been recognized as an accurate and reliable means of
evaluating cardiac anatomy and ventricular function.
Considerable progress has been made in the ﬁeld of
CMR, providing accurate evaluation of left ventric-
ular function parameters in coronary artery disease,
heart failure, hypertrophic cardiomyopathy, and
many other cardiac diseases [1–11]. Stress ﬁrst-pass
contrast-enhanced myocardial perfusion CMR can be
used to detect subendocardial ischemia and recent
studies have demonstrated the high diagnostic accu-
racy of stress myocardial perfusion CMR for detect-
ing signiﬁcant coronary artery disease [12–17].
Magnetic resonance angiography (MRA) has been
introduced as a method that can provide visualization
of all three major coronary arteries, coronary anom-
alies, coronary bypasses and the aorta within a single
three-dimensional acquisition [18–21]. CMR has
become the ﬁrst choice imaging modality in complex
congenital heart disease [22–26] and imaging great
vessels [27, 28].
Over the past years, contrast-enhanced CMR has
been used to visualize the transmural extent of
myocardial infarction with high spatial resolution
[29–34]. Infarcted myocardium appears hyper
enhanced compared with normal myocardium when
imaged by a late enhancement MRI technique with
the use of T1-weighted sequence after injection of
gadolinium chelates. Late gadolinium-enhanced
CMR can clearly delineate subendocardial infarction
and the transmural extent of delayed enhancement
potentially predicts functional outcome after revas-
cularization in acute myocardial infarction and
chronic ischemic heart disease [35, 36].
In a recent issue of the International Journal of
Cardiovascular Imaging, Larose et al. [37] investi-
gated the value of contrast-enhanced CMR in patients
following primary percutaneous coronary intervention
(PCI) because of ST-segment elevation myocardial
infarction (STEMI). The ﬁrst hours of STEMI are
critical: the earlier patient evaluation is performed—
preferably within hours—the more rapidly prognosis-
guiding therapies can be initiated. To determine
whether CMR is effective in risk stratiﬁcation in the
hyperacute phase of STEMI, the feasibility and safety
of CMR was studied in the hyperacute phase of
STEMI immediately after primary PCI. A total of 128
consecutive patients immediately after primary PCI
for STEMI, of whom 64 underwent CMR 12 h after
primary PCI versus 64 matched controls. Outcomes
were followed over 6 months. CMR in hyperacute
STEMI was not associated with in-hospital death,
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immediately after primary PCI did not increase
nephropathy. CMR did not increase major adverse
cardiac events(5vs.8%) orrecurrence ofangina(6vs.
8%) at 6 months. It was concluded that CMR imme-
diately after primary PCI is feasible and safe, allowing
very early risk stratiﬁcation in STEMI. In the current
study [37] a very low event rate was recorded both in-
hospital and during the 6 months following CMR
which was similar to that of primary PCI subjects not
undergoing CMR.
Until now, only a few studies have evaluated the
effects of primary PCI using contrast-enhanced CMR,
mostly focused on the effects of stents on CMR
imaging quality [38–40]. Kitabata et al. [41] showed
in 27 patients with anterior acute STEMI that the
microvascular resistance index, being a parameter of
microvascular damage, measured immediately after
primary PCI was a useful predictor for CMR-
determined infarct size. In the HEBE trial, a large,
multicentre, randomized trial performed in The
Netherlands, the effects of intracoronary infusion of
autologous bone marrow mononuclear cells after
primary PCI were evaluated with contrast-enhanced
CMR both in the acute phase of STEMI and 4 months
later [42, 43]. In these studies [41–43], CMR proved
to be feasible and there were no safety concerns for
CMR in the hyperacute phase.
The present study is therefore one of the leading
studies to demonstrate the feasibility and safety of
CMR in the hyperacute phase of STEMI after primary
PCI. Very early risk stratiﬁcation may be further
reﬁned safely by CMR, guiding the way for improved
tapering of therapies—such as stem cell therapy—in
the hyperacute phase of STEMI. Consequently,
performing CMR in the acute phase of STEMI offers
additional value in patients undergoing primary PCI.
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